Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is pleased to announce the appointment of Mr Willem Blijdorp as a Non-Executive Director of the Company. Mr Blijdorp’s appointment comes as Clinuvel prepares the commercial distribution of SCENESSE® for the rare disease erythropoietic protoporphyria (EPP) throughout the European Union. Mr Blijdorp is the founding member, majority shareholder and a current supervisory Director of B&S International NV, a privately owned Dutch group focused on the wholesale and international trading of luxury and fast moving consumer goods and pharmaceutical products. He managed B&S International for 27 years as CEO and remains actively…
Tuesday, 23 December 2014 10:38

European Commission approves SCENESSE®

Commercial distribution in preparation for European EPP patients Clinuvel Pharmaceuticals Ltd (ASX:CUV; XETRA-DAX: UR9; ADR: CLVLY) announced today that the European Commission has ratified the recommendation of the European Medicines Agency (EMA), granting marketing approval under exceptional circumstances to Clinuvel’s breakthrough drug SCENESSE® (afamelanotide 16mg). Clinuvel is now allowed to market SCENESSE® for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP) across the 31 EMA counties1. EPP is defined as the most severe clinical form of light and sunlight intolerance, often described as anaphylaxis to indoor and outdoor light sources. EPP patients are characterised by a lifelong…
Tuesday, 23 December 2014 08:47

Appendix 3Y - December 23 2014

Tuesday, 23 December 2014 08:46

Appendix 3B - December 23 2014

Italian, Swiss expert centres report "good clinical effectiveness and good safety" of drug in rare disease prior to broader access across Europe Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that long term observational data from the use of its first-in-class drug SCENESSE® (afamelanotide 16mg) in the rare disease erythropoietic protoporphyria (EPP) have been e-published in the British Journal of Dermatology. Two expert porphyria centres – the San Gallicano Dermatological Institute in Rome and the Triemli Municipal Hospital in Zurich – have reported on the use of SCENESSE® in 115 adult EPP patients treated for up to…
Friday, 05 December 2014 12:59

Form 604 - December 5, 2014

Thursday, 04 December 2014 17:47

Appendix 3Y - December 4 2014

Thursday, 04 December 2014 17:47

Appendix 3B - December 4 2014

Thursday, 04 December 2014 10:58

Investor Update Presentation - December 2014

Friday, 28 November 2014 12:52

Results of Meeting

Quick Links